Appointment of Finance Director

RNS Number : 8031A

Allergy Therapeutics PLC

10 June 2016

 

10 June 2016

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

Appointment of Finance Director

Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces the appointment of Nick Wykeman to the Board as Finance Director with immediate effect.

Mr Wykeman was most recently at Skyepharma PLC until August 2015 where he was the Group Financial Controller for six years. Prior to that, Mr Wykeman had also worked at Quest International (a part of ICI PLC) as the Group Financial Controller (Special Projects), following six years at Deloitte & Touche. Mr Wykeman has a BSc (Hons) in Economics and is a qualified accountant, being a member of the Institute of Chartered Accountants of England and Wales.

Mr Wykeman replaces Ian Postlethwaite, who, further to the announcement made on 17 March 2016, has now resigned from the Company and the Board with immediate effect.

Peter Jensen, Chairman of Allergy Therapeutics, said: "We welcome Nick to his role as Finance Director and look forward to his contribution to the Company as we continue to grow the business internationally on all fronts. His international experience in life sciences is well suited to the role and we're pleased to have attracted him to Allergy Therapeutics.

"We also thank Ian Postlethwaite for his fourteen, successful years with Allergy Therapeutics and wish him well for his future."

Nicolas Alexander Ulrich Wykeman, age 51, is currently a director of the following company:

Current Directorships

Wykeman Consulting BV

Allergy Therapeutics confirms that there are no further disclosures to be made in relation to Rule 17 of paragraph (g) of Schedule Two of the AIM Rules for Companies.

ENDS

For further information please contact:

Allergy Therapeutics

[phone]

Manuel Llobet, Chief Executive Officer

Panmure Gordon

[phone]

Freddy Crossley / Duncan Monteith, Corporate Finance

Tom Salvesen, Corporate Broking

Consilium Strategic Communications

[phone]

Mary-Jane Elliott / Ivar Milligan / Matthew Neal / Laura Thornton

[e-mail]

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international specialty pharmaceutical company focussed on the treatment and diagnosis of allergic disorders including immunotherapy vaccines that cure disease.  The Company sells proprietary products and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with MHRA-approved manufacturing facilities.  The Company employs c.420 employees and is listed on the London Stock Exchange (AIM:AGY).

For more information please see www.allergytherapeutics.com.

 

END

 

 

BOAUKSURNOANRUR